Sartorius Stedim Biotech Introduces Advanced System for Agar and Membrane Transfer
Sartorius Stedim Biotech (SSB), a leading global supplier for the pharmaceutical and biotech industries, is introducing Microsart @media to complement Microsart @vance, a product line for microbiological quality control in these sectors.
Microsart @media are agar media dishes for microbial limits testing according to the USP (Chapter <61>) and EP (Chapter 2.6.12). They are pre-filled with various agar media types, such as Tryptic Soy Agar or R2A Agar, sterile packaged and ready-to-use in combination with Microsart @filter units. Moreover, the Microsart @media features an innovative patented lid that allows touch-free transfer of the filter membrane onto the media without using any tweezers. In addition, easy access to the colonies after incubation is given due to the liftable lid. The intelligent design and ease of use eliminates almost all handling mistakes.
The combination of Microsart @media and Microsart @filters introduce a brand-new agar and membrane transfer concept. Thanks to their concerted development the matching Microsart @media active lid fits perfectly onto the Microsart @filter base. The few steps required between sampling and incubation save time and labor, while delivering more reliable results. The touch-free membrane transfer eliminates membrane manipulation and handling, thereby minimizing a major source of secondary contamination.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...